Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) Non Operating Income (2023 - 2026)

Alto Neuroscience has reported Non Operating Income over the past 4 years, most recently at $901000.0 for Q1 2026.

  • Quarterly results put Non Operating Income at $901000.0 for Q1 2026, up 77.71% from a year ago — trailing twelve months through Mar 2026 was $3.5 million (down 47.6% YoY), and the annual figure for FY2025 was $3.1 million, down 56.46%.
  • Non Operating Income reached $901000.0 in Q1 2026 per ANRO's latest filing, up from $873000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.3 million in Q2 2024 and bottomed at -$83000.0 in Q1 2023.
  • Median Non Operating Income over the past 4 years was $873000.0 (2025), compared with a mean of $977692.3.
  • The largest annual shift saw Non Operating Income soared 1267.47% in 2024 before it plummeted 63.39% in 2025.
  • Over 4 years, Non Operating Income stood at $548000.0 in 2023, then surged by 227.74% to $1.8 million in 2024, then plummeted by 51.39% to $873000.0 in 2025, then grew by 3.21% to $901000.0 in 2026.
  • Business Quant data shows Non Operating Income for ANRO at $901000.0 in Q1 2026, $873000.0 in Q4 2025, and $770000.0 in Q3 2025.